Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc. (NYSE: PEN) announced a definitive agreement for Boston Scientific to acquire Penumbra in a cash and stock transaction valuing the company at USD 374 per share, reflecting an enterprise value of approximately USD 14.5 billion. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.
Speed, safety, simplicity in head-to-toe clot removal
**Market Position
#1 in computer-assisted vacuum thrombectomy (CAVT) technology
Strategic Rationale & Market Context
Market Size: Global thrombectomy market valued at $3.2 billion (2026E), growing at 9.5 % CAGR
Competitive Landscape: Acquisition positions Boston Scientific against Stryker (Navien), Medtronic (Solitaire), and Terumo
Synergies: Combines Penumbra’s thrombectomy leadership with Boston Scientific’s vascular and peripheral intervention portfolio, creating a comprehensive stroke and PE treatment platform
Revenue Accretion: Expected to be accretive to BSX adjusted EPS by 2027
Financial Implications
Parameter
2026E
2027E
2028E
**Combined Thrombectomy Revenue
$1.8 billion
$2.1 billion
$2.5 billion
**Market Share (Post‑Acquisition)
35 %
38 %
42 %
**Cost Synergies
–
$150 million
$200 million
**Integration Costs
$75 million
$50 million
–
Forward‑Looking Statements This brief contains forward‑looking statements regarding transaction completion, revenue synergies, and market consolidation. Actual results may differ due to regulatory delays, integration challenges, and competitive responses.-Fineline Info & Tech
By Fineline Cube